Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases
The Special Issue of Biomedicines, entitled “Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases,” presents cutting-edge research findings, innovations, and insights into a wide range of topics related to the hepatobiliary system, such as the molecular mechanisms underlying disease p...
Sábháilte in:
| Formáid: | Online |
|---|---|
| Teanga: | Béarla |
| Foilsithe / Cruthaithe: |
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Ábhair: | |
| Rochtain ar líne: | ONIX_20230623_9783036577395_118 |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|
| _version_ | 1869520960331186176 |
|---|---|
| collection | Directory of Open Access Books |
| description | The Special Issue of Biomedicines, entitled “Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases,” presents cutting-edge research findings, innovations, and insights into a wide range of topics related to the hepatobiliary system, such as the molecular mechanisms underlying disease pathogenesis, diagnostic advancements, novel therapeutic approaches, and prevention strategies. The Special Issue comprises seven original articles and four review articles regarding NAFLD, primary biliary cholangitis (PBC), hepatitis B and C, and hepatocellular carcinoma (HCC). |
| format | Online |
| id | doab-20.500.12854ir-100886 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2023 |
| publishDateRange | 2023 |
| publishDateSort | 2023 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1008862024-03-30T23:22:46Z Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases Wang, Jinghua PBC autoantibodies glycoprotein gp210 nucleoporin p62 KLHL12 peptide hepatitis B virus hepatitis B X open reading frame HBX 3′ end region insertions deletions quasispecies next-generation sequencing cholestatic diseases gene therapy AAV PFIC RUNX1 NAFLD NASH metabolism systems biology ursodeoxycholic acid (UDCA) obeticholic acid (OCA) fibrates FXR agonists PPAR agonists budesonide transarterial chemoembolization radiofrequency ablation hepatocellular carcinoma type 2 diabetes mellitus non-alcoholic fatty liver disease transient hepatic elastography hepatic steatosis liver fibrosis primary biliary cholangitis obeticholic acid ursodeoxycholic acid farnesoid X receptor HCV DAA mitochondria genotoxicity side effect chronic hepatitis B nucleos(t)ide analogs miR-125b biomarker fibrosis score fatty liver cirrhosis females gender liver n/a thema EDItEUR::M Medicine and Nursing The Special Issue of Biomedicines, entitled “Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases,” presents cutting-edge research findings, innovations, and insights into a wide range of topics related to the hepatobiliary system, such as the molecular mechanisms underlying disease pathogenesis, diagnostic advancements, novel therapeutic approaches, and prevention strategies. The Special Issue comprises seven original articles and four review articles regarding NAFLD, primary biliary cholangitis (PBC), hepatitis B and C, and hepatocellular carcinoma (HCC). 2023-06-23T09:50:43Z 2023-06-23T09:50:43Z 2023 book ONIX_20230623_9783036577395_118 9783036577395 9783036577388 https://directory.doabooks.org/handle/20.500.12854/100886 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/7351 https://mdpi.com/books/pdfview/book/7351 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-7738-8 10.3390/books978-3-0365-7738-8 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036577395 9783036577388 190 Basel open access |
| spellingShingle | PBC autoantibodies glycoprotein gp210 nucleoporin p62 KLHL12 peptide hepatitis B virus hepatitis B X open reading frame HBX 3′ end region insertions deletions quasispecies next-generation sequencing cholestatic diseases gene therapy AAV PFIC RUNX1 NAFLD NASH metabolism systems biology ursodeoxycholic acid (UDCA) obeticholic acid (OCA) fibrates FXR agonists PPAR agonists budesonide transarterial chemoembolization radiofrequency ablation hepatocellular carcinoma type 2 diabetes mellitus non-alcoholic fatty liver disease transient hepatic elastography hepatic steatosis liver fibrosis primary biliary cholangitis obeticholic acid ursodeoxycholic acid farnesoid X receptor HCV DAA mitochondria genotoxicity side effect chronic hepatitis B nucleos(t)ide analogs miR-125b biomarker fibrosis score fatty liver cirrhosis females gender liver n/a thema EDItEUR::M Medicine and Nursing Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases |
| title | Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases |
| title_full | Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases |
| title_fullStr | Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases |
| title_full_unstemmed | Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases |
| title_short | Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases |
| title_sort | advances in pathogenesis and therapeutics of hepatobiliary diseases |
| topic | PBC autoantibodies glycoprotein gp210 nucleoporin p62 KLHL12 peptide hepatitis B virus hepatitis B X open reading frame HBX 3′ end region insertions deletions quasispecies next-generation sequencing cholestatic diseases gene therapy AAV PFIC RUNX1 NAFLD NASH metabolism systems biology ursodeoxycholic acid (UDCA) obeticholic acid (OCA) fibrates FXR agonists PPAR agonists budesonide transarterial chemoembolization radiofrequency ablation hepatocellular carcinoma type 2 diabetes mellitus non-alcoholic fatty liver disease transient hepatic elastography hepatic steatosis liver fibrosis primary biliary cholangitis obeticholic acid ursodeoxycholic acid farnesoid X receptor HCV DAA mitochondria genotoxicity side effect chronic hepatitis B nucleos(t)ide analogs miR-125b biomarker fibrosis score fatty liver cirrhosis females gender liver n/a thema EDItEUR::M Medicine and Nursing |
| topic_facet | PBC autoantibodies glycoprotein gp210 nucleoporin p62 KLHL12 peptide hepatitis B virus hepatitis B X open reading frame HBX 3′ end region insertions deletions quasispecies next-generation sequencing cholestatic diseases gene therapy AAV PFIC RUNX1 NAFLD NASH metabolism systems biology ursodeoxycholic acid (UDCA) obeticholic acid (OCA) fibrates FXR agonists PPAR agonists budesonide transarterial chemoembolization radiofrequency ablation hepatocellular carcinoma type 2 diabetes mellitus non-alcoholic fatty liver disease transient hepatic elastography hepatic steatosis liver fibrosis primary biliary cholangitis obeticholic acid ursodeoxycholic acid farnesoid X receptor HCV DAA mitochondria genotoxicity side effect chronic hepatitis B nucleos(t)ide analogs miR-125b biomarker fibrosis score fatty liver cirrhosis females gender liver n/a thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20230623_9783036577395_118 |